HEXACYCLONATE SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C9H15O3.Na
Molecular Weight	194.2034
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].OCC1(CC([O-])=O)CCCCC1

InChI

InChIKey=YPKROQTVZNJPNX-UHFFFAOYSA-M

InChI=1S/C9H16O3.Na/c10-7-9(6-8(11)12)4-2-1-3-5-9;/h10H,1-7H2,(H,11,12);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	C9H15O3
Molecular Weight	171.2136
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7933781 | https://www.ncbi.nlm.nih.gov/pubmed/1307777

Hexacyclonic Acid (aka gevilon) has been clinically demonstrated to produce hypolipidemic effects. It has been investigated as a treatment for coronary heart disease, and hypertensive disease with severe lipid metabolic disturbances. Gevilon has been found to have a hypolipidemic effect in reducing the levels of total cholesterol, beta-cholesterol, triglycerides, increasing alpha-cholesterol levels and normalizing the atherogenicity coefficient; especially in patients with Type IIb dyslipoproteinemia.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hyperlipoproteinemia 9 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1307777	Primary		Not Provided 511	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Hypolipidemic effect of gevilon].	1993	7933781
Therapeutic effect of gevilon in patients with hyperlipoproteinaemia.	1992-04-01	1307777
[ELECTROENCEPHALOGRAPHIC EXPERIMENTATION WITH 2 NEW ACTIVATORS: TOCEN AND HEXACYCLONATE (GEVILON)].	1963	14163606
Adjunctive treatment of the chronic alcoholic with hexacyclonate sodium.	1962-05	13878809
Pharmaco-motivation of the geriatric patient: a preliminary report on hexacyclonate.	1962-01	14476295
Effects of hexacyclonate on regressed patients.	1961-10	13923435
[Sodium hexacyclonate as coadjuvant in the treatment and rehabilitation of the chronic alcoholic].	1961-06-20	13692926
[Special clinical a spects of old age and their treatment with sodium-beta,beta-pentamethylene-beta-hydroxybutyrate (Gevilon) in internal medicine].	1960-10-28	13725460

Patents

Sample Use Guides

In Vivo Use Guide

Patients with hyperlipoproteinemia were divided according to hyperlipoproteinemia type IIA, IIB, and IV. After one month of isocaloric diet, the patients were given a single night gevilon dose of 900 mg for a period of 3 months. In all groups increased levels of cholesterol, beta-lipoproteins and triglycerides were significantly reduced after 3 months of gevilon treatment. In all patients, the HDL/LDL ratio increased close to normal values.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:30:11 GMT 2025` Edited by `admin` on `Wed Apr 02 07:30:11 GMT 2025`
Record UNII	6XI46H39BZ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SODIUM HEXACYCLONATE

Preferred Name

English

HEXACYCLONATE SODIUM

Common Name

English

SODIUM 1-(HYDROXYMETHYL)CYCLOHEXANEACETATE

Systematic Name

English

1-(HYDROXYMETHYL)CYCLOHEXANEACETATE SODIUM SALT

Common Name

English

HEXACYCLONATE SODIUM [MI]

Common Name

English

sodium hexacyclonate [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47795